Floatz logo

vg2025

Carcinomatosis

M.D. Anderson Cancer CenterPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

32 Active assets in the Carcinomatosis cohort.

Asset / SponsorPhaseRating
Eloxatin
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 3BB
FLUOROURACILUM
Ciusss de L'Est de l'Île de Montréal
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 3BB
MITOMYCIN C
H. Lee Moffitt Cancer Center and Research Institute
Phase 4BB
Irinotecan
Catharina Ziekenhuis Eindhoven
Phase 3BB

View all 42 →

Same molecule, other indications

vg2025 is also rated in:

colorectal cancerDormant
CCC
Indicative ·
48 / 100
View asset →
Advanced Malignant Solid TumorDormant
C
Indicative ·
39 / 100
View asset →
neoplasmDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →